Clinical trials: Type 2 Diabetic
Type 2 Diabetes
A Diabetes Study to Treat A Population Previously Not at Target
This study will assess if customizing the start dose of rosuvastatin appropriate for the degree of LDL-C reduction required, would achieve LDL-C target of ≤ 2.0 mmol/L quickly with either no titration or just one titration step…
- Trial name
- ADAPT (NCT00747149)
- Testing
- Rosuvastatin
- Where
- 84 sites in Canada
- Volunteers
- 598 people
- Sponsor
- AstraZeneca
Type 1 Diabetes, Type 2 Diabetes
Smart Glucose Meter Project
Currently, in the U.S., 1 in 3 males and 2 in 5 females born after 2000 are expected to develop diabetes during his or her lifetime.
- Trial name
- NCT01341587
- Testing
- Telcare Blood Glucose Meter (BGM)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Maryland, Baltimore
Physical Inactivity, Type2 Diabetes Mellitus
Behavioral Change Communication for Physical Activity Among Females With Type2 Diabetes Mellitus
The marked discrepancy between predicted and actual prevalence of Type2 diabetes Mellitus (DM) with the actual cases rising earlier than expected, underscore the continuing relevance of tailored awareness and management…
- Trial name
- RCT (NCT00690326)
- Testing
- Behavioral change communication model(BCC) to promote physical activity, pamphlet-The printed pamphlet,'Physical activity:To control blood sugar/ Diabetes Mellitus'
- Where
- India
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Thiruvananthapuram Medical College
Diabetes, Diabetes Mellitus, Type 2
A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients
This trial is conducted globally. The aim of this trial is to compare stepwise insulin intensification of biphasic insulin aspart (BIAsp) 30 and basal-bolus therapy with insulin glargine and insulin aspart in insulin naïve type 2…
- Trial name
- NCT02453685
- Testing
- biphasic insulin aspart 30, insulin glargine, insulin aspart
- Where
- 41 sites in Australia, Bulgaria and 7 more
- Volunteers
- 335 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-401)
This is a multi-center, observational, retrospective and cross-sectional study to be conducted in a cohort of consecutively selected participants with Type 2 diabetes mellitus (DM) who have been treated with sulphonylurea (SU)…
- Trial name
- NEEDS (NCT01285076)
- Testing
- Other: Retrospective chart review; one participant encounter visit.
- Where
- Taiwan
- Volunteers
- 834 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Comparison Effects Of Different Exercise Approaches On Type 2 DM Women
Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic diseases with a complex, multifactorial etiology, and is a chronic disease with various clinical and biochemical manifestations.
- Trial name
- NCT05479435
- Testing
- Blue Prescription Exercise Program, Video Based Home Exercise Program, Supervised Group Exercise Program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Istanbul Medipol University Hospital
Diabetes Mellitus, Type 2, Newly Diagnosed
Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients
The purpose of this study is to investigate and evaluate the effects of different interventions (1. exenatide, 2. insulin, 3. thiazolidinedione) on glycemic control and β-cell function in newly diagnosed drug-naïve type 2…
- Trial name
- NCT01147627
- Testing
- exenatide injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R, Pioglitazone
- Where
- 25 sites in China
- Volunteers
- 416 people
- Sponsor
- Sun Yat-sen University
Type 2 Diabetes Mellitus
Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of TA-7284 orally administered once daily for 15 days (1 day followed by a 1 day washout period and then 14 consecutive days).
- Trial name
- NCT00707954
- Testing
- TA-7284
- Where
- Japan
- Volunteers
- 61 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus
Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin
This is a study to evaluate the safety, tolerability, and activity of OAP-189 in subjects with type 2 diabetes who are taking metformin for their diabetes.
- Trial name
- 3283K1-1008-US (NCT00970593)
- Testing
- OAP-189
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Pfizer
Diabetes Mellitus, Diabetes Mellitus, Type 2
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Diseases
- Trial name
- NCT01301456
- Testing
- PF-04856883
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
Supplements containing goldenseal, a perennial herb native to North America, have consistently ranked among the top 20 highest selling natural products throughout the last decade.
- Trial name
- NCT05081583
- Testing
- Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington State University
Type 2 Diabetes Mellitus
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
The purpose of this study was to evaluate the efficacy and safety of 24-week treatment with metformin hydrochloride 500 mg once daily added on to alogliptin (SYR-322) 25 mg in type 2 diabetic patients with inadequate glycemic…
- Trial name
- NCT02068443
- Testing
- Alogliptin, Metformin hydrochloride
- Where
- 27 sites in Japan
- Volunteers
- 374 people
- Sponsor
- Takeda
Diabetes Mellitus Type 2
Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
Vildagliptin and Sitagliptin both belong to the class of DPP-4 inhibitors, but differ in their pharmacokinetic profile as well as in their approved application (Vildagliptin, 2x 50 mg daily, Sitagliptin, 1x 100 mg daily).
- Trial name
- CGM-VISIT (NCT01686932)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 11 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
Characteristics of Glargine in Type 2 Diabetics
The study is to determine the dose response relationship of insulin glargine in type 2 diabetes over a 24-hour period and measuring the differences in glucose production among the differing doses of glargine.
- Trial name
- NCT00574912
- Testing
- Insulin Glargine 0.5 u/kg body wt SC, Insulin Glargine 1.0 u/kg body wt SC, Insulin Glargine 1.5 u/kg body wt SC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University Medical Center
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Among adult individuals with type 2 diabetes mellitus and at risk for heart failure with impaired relaxation of the heart mildly reduced kidney filtration function (Type 4 cardiorenal syndrome) this trial will evaluate the…
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
- Trial name
- NCT02251431
- Testing
- BYDUREON
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Baylor Research Institute
Type 2 Diabetes Mellitus
A Study for Type 2 Diabetic Patients
The purpose of the study is to compare the insulin lispro low mixture (1, 2 or 3 daily injections) with insulin glargine (alone or with 1, 2 or 3 insulin lispro daily injections) on lowering the blood sugar level
- Trial name
- NCT00548808
- Testing
- Insulin lispro low mixture, Insulin glargine, Insulin lispro
- Where
- 25 sites in Australia, Brazil and 5 more
- Volunteers
- 426 people
- Sponsor
- Eli Lilly and Company
Hypertension, Diabetes Mellitus, Type II
Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control
This is a 24-week, prospective, multicenter, open-label, single-arm study to assess the effect of bisoprolol on glycemic level in Type 2 diabetes mellitus (T2DM) controlled subjects with hypertension.
- Trial name
- GIANT (NCT01066039)
- Testing
- Bisoprolol
- Where
- South Korea
- Volunteers
- 202 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Diabetes Mellitus Type 2
Evaluation of CONTOUR® USB BGMS on Glycaemic Control in Insulin-treated Diabetic Patients
The purpose of this study is to evaluate if the use of the CONTOUR Next USB BGMS system with AutoLog and Trends features and integrated data management software (Glucofacts ™ DELUXE) enables behavioral changes that may lead to…
- Trial name
- CONGO (NCT01588106)
- Where
- 16 sites in Germany
- Volunteers
- 154 people
- Sponsor
- GWT-TUD GmbH
Diabetes, Obesity
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in…
- Trial name
- NCT04617275
- Testing
- PF-06882961
- Where
- 38 sites in United States
- Volunteers
- 151 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263
- Trial name
- NCT01128621
- Testing
- GSK1292263, Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline